In colorectal cancer cells with mutated KRAS, treatment with cetuximab (anti-EGFR mAbs) or regorafenib (oral multikinase inhibitor) alone does not produce more than 22% of apoptosis after 24 h of treatment [30]. Here, KRAS is linked to colorectal cancer.